Effect of Delayed-Release Dimethyl Fumarate on Total Disability Burden in the CONFIRM Study of Relapsing-Remitting Multiple Sclerosis: Area Under the Curve Analysis of Changes from Baseline in Expanded Disability Status Scale Scores (P7.233)
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
OBJECTIVE: Quantify the effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on total disability burden in the Phase 3 CONFIRM study of relapsing-remitting multiple sclerosis (RRMS) using area under the Expanded Disability Status Scale (EDSS)-time curve (AUC) to integrate all measured EDSS progression and improvement over the 2-year study period. BACKGROUND: Quantifying on-treatment disability changes in RRMS patients over time may inform treatment decisions. Compared with traditional disability progression analysis, AUC analysis contains more information about the cumulative extent of disability over time because it considers all EDSS scores over the study period. DESIGN/METHODS: RRMS patients were randomized to placebo, DMF 240 mg BID or TID, or glatiramer acetate (GA) for up to 2 years. EDSS scores were assessed at 12-week intervals. For AUC analysis, EDSS change scores were computed relative to baseline (week 0). AUC of EDSS change scores was calculated for all patients, with imputation applied for missing scores; treatment groups were compared in mean EDSS AUC change, adjusted for covariates, using ANCOVA ranked data. Positive AUC change indicates net worsening in EDSS from baseline; negative AUC change indicates net improvement in EDSS from baseline. RESULTS: A total of 363, 359, and 350 patients received placebo, DMF BID, and GA, respectively, in CONFIRM. Two-year mean (standard error of the mean [SE]) AUC change in EDSS was 0.075 (0.062) for placebo. Compared with placebo, the mean differences in AUC change in EDSS (SE) were 0.110 (0.084) and 0.034 (0.090) for DMF BID (P=0.0375) and GA (P=0.5523), respectively. Results for the Phase 3 DEFINE study will also be reported. CONCLUSIONS: AUC analysis suggests a positive benefit of DMF on a measure of total disability burden. Patients receiving DMF had a better overall experience with respect to disability compared with placebo. Study Supported by: Biogen Idec
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it